Alpha 2.0
Login Register
» Authors » H C van Santvoort

H C van Santvoort

Explore the profile of H C van Santvoort including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 58
Citations 831
Followers 0
Related Specialties
General Surgery
General Medicine
Oncology
Top 10 Co-Authors
M G Besselink
I Q Molenaar
O R Busch
B Groot Koerkamp
H G Gooszen
J W Wilmink
T L Bollen
L A Daamen
M G H Besselink
M W J Stommel
Published In
Br J Surg
Trials
Ned Tijdschr Geneeskd
Pancreatology
Eur J Surg Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
Standard versus Pre-emptive Antibiotic Treatment to Reduce the Rate of Infectious Outcomes after Whipple resection (SPARROW): a study protocol for a multicentre, open-label, randomised controlled trial
Droogh D, de Boer M, van Prehn J, Putter H, Bonsing B, Bosscha K, et al.
Trials . 2025 Mar; 26(1):88. PMID: 40083036
Background: Consensus and evidence on the impact of pre-emptive antibiotic treatment after pancreatoduodenectomy is lacking, which is reflected by contradictory recommendations in (inter)national guidelines and current clinical practice. Pre-emptive antibiotic...
2.
Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol
Stoop T, Seelen L, van t Land F, van der Hout A, Scheepens J, Ali M, et al.
BMC Cancer . 2025 Feb; 25(1):299. PMID: 39972248
Background: The introduction of (m)FOLFIRINOX and gemcitabine-nab-paclitaxel has changed the perspective for patients with locally advanced pancreatic cancer (LAPC). Consequently, in experienced centres 23% of patients with LAPC undergo a...
3.
Feasibility of an < 24 h discharge pathway with tele-monitoring after elective colectomies: a pilot study
Smalbroek B, Dijksman L, Poelmann F, van Santvoort H, Weijs T, Wijffels N, et al.
Surg Endosc . 2025 Jan; 39(3):1848-1857. PMID: 39838143
Introduction: Implementation of enhanced recovery after surgery principles has led to exploration of ambulatory pathways in surgery, including gastrointestinal surgery. However, implementation of ambulatory pathways after colorectal surgery has not...
4.
Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert survey and case vignette study
Biesma N, Graus M, Cirkel G, Besselink M, de Groot J, Koerkamp B, et al.
Eur J Surg Oncol . 2024 Dec; 51(3):109544. PMID: 39689462
Introduction: Adjuvant chemotherapy improves survival in patients with resected pancreatic ductal adenocarcinoma (PDAC). The decision to initiate chemotherapy involves both patient and physician factors, decision-specific criteria, and contextual considerations. This...
5.
Correction: Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an international randomized controlled trial according to the Trials within...
Daamen L, van Goor I, Groot V, Andel P, Brosens L, Busch O, et al.
Trials . 2024 Jul; 25(1):456. PMID: 38970096
No abstract available.
6.
Prediction of Isolated Local Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Nationwide Study
van Goor I, Andel P, Buijs F, Besselink M, Bonsing B, Bosscha K, et al.
Ann Surg Oncol . 2024 Jun; 31(12):8264-8275. PMID: 38937412
Background: Distinguishing postoperative fibrosis from isolated local recurrence (ILR) after resection of pancreatic ductal adenocarcinoma (PDAC) is challenging. A prognostic model that helps to identify patients at risk of ILR...
7.
Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an international randomized controlled trial according to the Trials within Cohorts design
Daamen L, van Goor I, Groot V, Andel P, Brosens L, Busch O, et al.
Trials . 2024 Jun; 25(1):401. PMID: 38902836
Background: Disease recurrence remains one of the biggest concerns in patients after resection of pancreatic ductal adenocarcinoma (PDAC). Despite (neo)adjuvant systemic therapy, most patients experience local and/or distant PDAC recurrence...
8.
Implementation and outcome of minimally invasive pancreatoduodenectomy in Europe: a registry-based retrospective study - a critical appraisal of the first 3 years of the E-MIPS registry
Emmen A, de Graaf N, Khatkov I, Busch O, Dokmak S, Boggi U, et al.
Int J Surg . 2024 Jan; 110(4):2226-2233. PMID: 38265434
Background: International multicenter audit-based studies focusing on the outcome of minimally invasive pancreatoduodenectomy (MIPD) are lacking. The European Registry for Minimally Invasive Pancreatic Surgery (E-MIPS) is the E-AHPBA endorsed registry...
9.
Development of pancreatic diseases during long-term follow-up after acute pancreatitis: a post-hoc analysis of a prospective multicenter cohort
de Rijk F, Sissingh N, Boel T, Timmerhuis H, de Jong M, Pauw H, et al.
J Gastroenterol Hepatol . 2024 Jan; 39(4):674-684. PMID: 38191176
Background And Aim: More insight into the incidence of and factors associated with progression following a first episode of acute pancreatitis (AP) would offer opportunities for improvements in disease management...
10.
Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial
van Dam J, Verkolf E, Dekker E, Bonsing B, Bratlie S, Brosens L, et al.
BMC Cancer . 2023 Aug; 23(1):728. PMID: 37550634
Background: Surgical resection followed by adjuvant mFOLFIRINOX (5-fluorouracil with leucovorin, irinotecan, and oxaliplatin) is currently the standard of care for patients with resectable pancreatic cancer. The main concern regarding adjuvant...